Stylus Medicine Inc., a biotechnology company dedicated to developing transformative in vivo genetic medicines, has emerged from stealth with $85 million in financing

to advance its in vivo genetic medicines platform and pipeline of in vivo therapeutic programs.

The company’s engineering platform combines sequence-specific genome integration with cell-targeted lipid nanoparticle (LNP) delivery to enable durable, flexible, and scalable in vivo cell engineering, overcoming major limitations of ex vivo cell therapy manufacturing and expanding the reach of transformative genetic medicines.

“Stylus was established to reimagine how genetic medicines reach patients. At the core of our approach are three defining features of an ideal therapy: safe and targeted in vivo delivery, specific integration, and durable expression of a therapeutic payload,” said Emile Nuwaysir, Ph.D., Chairman and CEO of Stylus. “By removing the complexity of ex vivo and viral manufacturing, we will dramatically simplify patient treatment. Our goal is to bring the life-saving promise of genetic medicines to every patient in need, starting with CAR-T therapies.”

The Company’s leadership includes Emile Nuwaysir, Ph.D., Chairman and Chief Executive Officer, and Jason Fontenot, Ph.D., Chief Scientific Officer.